Why a US Ingredient Technology Company Chose Ireland for Its European Research Base

CoreFX Ingredients, a biotech company that develops formulation technology for nutritional ingredients, has established a European headquarters, CoreNhanced Biotechnology Limited, in County Cork, Ireland, in partnership with the state agricultural and food research agency Teagasc at its Moorepark campus.¹

The new operation launches with 3 scientists and is supported by Enterprise Ireland, the government agency that has backed the company's growth strategy since 2023.¹ For manufacturers sourcing formulation technology, the move signals an ingredient-technology supplier expanding its research footprint into a European research ecosystem built specifically around food and biotechnology, rather than simply opening a sales or distribution office.

"Returning to Ireland to establish our European headquarters is personally meaningful, but this decision was driven by much more than my own roots," said Denis Neville, CoreFX’s founder and CEO officer, in the company's announcement. "Ireland has become one of the world's leading centers for food science, biotechnology, and innovation. By combining the scientific excellence of Teagasc Moorepark with Enterprise Ireland's vision and support, we are creating an innovation platform that will accelerate how breakthrough nutritional technologies move from research into commercial reality for customers across Europe and beyond."¹

What Is CoreFX Building in Ireland, and Why Does the Research Partner Matter?

The new entity is built around collaboration with Teagasc Moorepark, a publicly funded agricultural and food research campus in County Cork that has operated as a center for dairy and food science research, rather than around a standalone corporate laboratory.

Cara Maloney, PhD, a scientist with more than 5 years of postdoctoral research experience and 26 peer-reviewed publications, will lead the Irish operation's scientific work, while Trevor Dunne, who has more than 20 years of international leadership experience, will serve as managing director for Europe.¹

Mark Christal, executive director of Enterprise Ireland, framed the agency's involvement as a continuation of existing support rather than a new relationship: "Their investment is a strong endorsement of Ireland's food science and biotechnology sector. Since 2023, Enterprise Ireland has supported the company's growth strategy, and this new European headquarters, developed alongside Teagasc Moorepark, represents the next stage of that journey," he noted.

Enterprise Ireland's stated mission centers on helping companies scale internationally through Irish operations, a mandate broadly consistent with a US company establishing an Ireland-based European base.²

What Formulation Problems Is the Company's Technology Meant to Address?

CoreFX's proprietary CoreNhanced platform is intended to improve how bioactive molecules perform during manufacturing, throughout shelf life, and within the body, addressing issues involving stability, protective shielding, transport, functionality, sensory qualities, and manufacturing efficiency.

Why Do Stability and Bioavailability Remain Persistent Problems in Ingredient Formulation?

The formulation challenges CoreFX describes align with a broader, well-documented problem in nutraceutical science. A 2026 review in Frontiers in Nutrition noted that many bioactive compounds show poor physicochemical stability and low bioavailability, remaining highly sensitive to oxygen, light, moisture, temperature, and pH changes that degrade activity during processing and storage, while also facing poor water solubility and limited gastrointestinal absorption once consumed.³

That same review found that even established encapsulation methods often suffer from low efficiency and inconsistent release control, which is the general category of problem CoreFX says its platform targets, though the announcement itself provides no data specific to the company's approach.

What Hasn't Been Disclosed About This Expansion?

The announcement does not include a capital investment figure, projected headcount growth beyond the initial 3 scientists, or a timeline for when commercial output from the Irish facility might reach customers. It also does not name specific finished-product categories or brand partners that will use technology developed at the new site. Because CoreNhanced is not itself a marketed ingredient with published efficacy data, the platform's formulation claims should be understood as a description of intended function rather than as evidence the technology has demonstrated those outcomes in a specific product.

References

1. CoreFX expands global reach with new European Innovation Headquarters in Ireland, supported by Enterprise Ireland. PR Newswire. September 15, 2026. Accessed September 15, 2026. https://www.prnewswire.com/news-releases/corefx-expands-global-reach-with-new-european-innovation-headquarters-in-ireland-supported-by-enterprise-ireland-302878267.html

2. Irish Enterprise Development Agency. Enterprise Ireland. Accessed September 2026. https://www.enterprise-ireland.com/en/about-enterprise-ireland

3. Kumari K, Tripathy S, Srivastav PP. Emerging encapsulation techniques for controlled and targeted delivery of bioactive compounds in food and nutraceutical systems. Front Nutr. 2026;13:1826702. doi:10.3389/fnut.2026.1826702